CanSino Biologics Inc has become the first company to secure a patent for its COVID-19 vaccine in China

CanSino Biologics Inc. a Chinese vaccine maker, has emerged as the rising star of the Hong Kong market after its COVID-19 clinical trial application was approved by Health Canada, the country's federal health policy department.